Programa de trasplante de médula ósea

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. A Study of Patients Treated for Chronic Granulomatous Disease Since 1995

   Rochester, Minn.

   Chronic granulomatous disease (CGD) is an inherited immune system abnormality in which bone marrow transplantation has been shown to be curative. However the risks of transplantation are high and not all patients with CGD may need to undergo this high risk procedure. The purpose of this study is to determine the long term medical condition and daily functioning of patients with CGD after a transplant and if possible, compare these results to patients who do not undergo a transplant.

2. A Study to Assess Feasibility and Benefit of a Patient-reported Outcomes Quality of Life Tool for Hematology and Medical Oncology

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the feasibility and benefit of a patient-reported outcomes quality of life tool for hematology and medical oncology.

3. Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML

   Rochester, Minn., Jacksonville, Fla.

   The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care.

4. Digital Stories and Psychosocial Wellbeing in Stem Cell Transplant Patients

   Scottsdale/Phoenix, Ariz.

   The proposed research will use a double-blind randomized controlled design to pilot test a model for how stories shared by a panel of HCT survivors impact the psychosocial well-being of the digital stories (DS) intervention condition of 55 patients who recently underwent HCT and their respective caregivers compared with 55 people in an information control (IC) condition and their caregivers (total 220 participants; N=110 per condition). Participants, recruited from the Mayo Clinic Arizona Cancer Center, will be randomly assigned to one of two conditions: the DS intervention or the IC video condition. Participants will questionnaires at baseline (T1), after the 4-week intervention (T2), and 3 months (100 days) later (T3).

5. A Study to Evaluate Itacitinib for Low Risk Graft-vs-Host Disease (GVHD)

   Rochester, Minn.

   The purpose of this study is to test whether patients with low risk Great-vs-Host Disease (GVHD) can be successfully treated without steroids. Patients who participate with this study will be treated with itacitinib instead of steroids. Itacitinib is an experimental drug with an excellent safety record and appears to have activity as a GVHD treatment. A new blood test can identify patients whose GVHD is most likely to respond to well to treatment (low risk GVHD).

6. Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study)

   Rochester, Minn.

   The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis.

7. A Study to Assess Older Adults Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality After Allogeneic Transplantation for Older Adults (CHARM)

   Rochester, Minn.

   The purpose of this study is to determine the set of assessments and biomarkers that could together constitute a robust and valid composite health risk model for accurate personalized estimation of one year NRM.

8. A Study to Evaluate Daratumumab in Treating Transplant-Eligible Participants with Multiple Myeloma

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This phase II trial studies how well daratumumab works in treating transplant-eligible participants with multiple myeloma. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread.

9. A Study to Evaluate Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation

   Rochester, Minn.

   The primary purpose of this study is to estimate and compare overall survival between the two arms:  patients who are Very Likely to find a Matched Unrelated Donor (MUD) versus those who are Very Unlikely to find a MUD.

    

10. A Study to Evaluate the Skin Microbiome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

    Jacksonville, Fla.

    The primary purpose of this study is to assess and analyze the skin microbiota composition (abundance, diversity, specific organisms) in patients in the pre-and post-alloHSCT setting.